The incretin-bone axis: molecular mechanisms and clinical implications. [PDF]
Front Endocrinol (Lausanne)Muscarà A, Bellone F, Rossi M.
europepmc +1 more source
Osteoporosis therapies and coronary risk: insights from vascular calcification biology and sclerostin signaling. [PDF]
Front Endocrinol (Lausanne)Weng S +7 more
europepmc +1 more source
Sclerostin in Vascular Calcification: Hypoxia-Driven Regulation and Therapeutic Modulation by Natural Products. [PDF]
Curr Atheroscler RepYeon S +5 more
europepmc +1 more source
Exercise-responsive crosstalk within local muscle-bone units in osteosarcopenia: from mechanotransduction to secretome signalling. [PDF]
Front PhysiolGuan Z +6 more
europepmc +1 more source
Early bone-formation response to sclerostin antibody is altered by prior antiresorptive treatment in ovariectomized rats. [PDF]
JBMR PlusBédard A +10 more
europepmc +1 more source
Osteocytes in the Metastatic Bone Niche: Mechanistic Pathways and Therapeutic Targets. [PDF]
Pharmaceuticals (Basel)Dabaliz A +4 more
europepmc +1 more source
Mechanisms limiting the long-term anabolic effects of teriparatide (PTH 1-34) on bone. [PDF]
JBMR PlusSchmal C, Wu JY, Jafari A.
europepmc +1 more source
Osteocytes orchestrate browning: emerging signals in bone-fat crosstalk: a systematic review. [PDF]
Front Endocrinol (Lausanne)Anees H +6 more
europepmc +1 more source
Advanced glycation end-products and sclerostin are elevated across diabetes phenotypes and associated with vertebral fractures in type 2 diabetes. [PDF]
BMC Endocr DisordTaskin Kursun S, Imre E, Gogas Yavuz D.
europepmc +1 more source